Abstract
Pulmonary hypertension can occur idiopathically as a primary disorder of the pulmonary circulation or more commonly, it can exist as a haemodynamic manifestation of a wide variety of pulmonary and cardiovascular diseases, including acute lung injury, chronic obstructive lung disease, congenital heart disease, mitral stenosis, chronic left-sided congestive heart failure and connective tissue diseases such as scleroderma. Pulmonary hypertension is associated with changes in vascular tone as well as vascular structure, with the relative contribution of each dependent upon the aetiology of the increased pulmonary vascular resistance. Most currently available treatment utilise anticoagulants as well as vasodilator drugs that only attenuate the vasoconstrictive component of the disease. The latter category includes oral calcium channel blockers, iv. and aerosolised prostacyclin analogues and inhaled nitric oxide but all three classes of vasodilators have disadvantages and limitations. Treatment with vasodilators is often ineffective in patients with longstanding pulmonary hypertension in which structural changes contribute significantly to the pulmonary hypertension, blood flow obstruction and right heart failure. In view of the immense clinical need, new therapies are being developed by pharmaceutical companies to treat pulmonary hypertension. This update will focus on the current development status of endotheli receptor antagonists and nitric oxide donors for the treatment of pulmonary hypertension.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1291-1308 |
| Number of pages | 18 |
| Journal | Expert Opinion on Investigational Drugs |
| Volume | 10 |
| Issue number | 7 |
| DOIs | |
| State | Published - 2001 |
| Externally published | Yes |
Fingerprint
Keywords
- Endothelin
- Endothelin receptors
- ET and ET antagonists
- Nitric oxide
- NO donors
- Pulmonary hypertension
ASJC Scopus subject areas
- Pharmacology
Cite this
Therapeutic potential of endothelin receptor antagonists and nitric oxide donors in pulmonary hypertension. / Tilton, Ronald; Brock, T. A.; Dixon, R. A F.
In: Expert Opinion on Investigational Drugs, Vol. 10, No. 7, 2001, p. 1291-1308.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Therapeutic potential of endothelin receptor antagonists and nitric oxide donors in pulmonary hypertension
AU - Tilton, Ronald
AU - Brock, T. A.
AU - Dixon, R. A F
PY - 2001
Y1 - 2001
N2 - Pulmonary hypertension can occur idiopathically as a primary disorder of the pulmonary circulation or more commonly, it can exist as a haemodynamic manifestation of a wide variety of pulmonary and cardiovascular diseases, including acute lung injury, chronic obstructive lung disease, congenital heart disease, mitral stenosis, chronic left-sided congestive heart failure and connective tissue diseases such as scleroderma. Pulmonary hypertension is associated with changes in vascular tone as well as vascular structure, with the relative contribution of each dependent upon the aetiology of the increased pulmonary vascular resistance. Most currently available treatment utilise anticoagulants as well as vasodilator drugs that only attenuate the vasoconstrictive component of the disease. The latter category includes oral calcium channel blockers, iv. and aerosolised prostacyclin analogues and inhaled nitric oxide but all three classes of vasodilators have disadvantages and limitations. Treatment with vasodilators is often ineffective in patients with longstanding pulmonary hypertension in which structural changes contribute significantly to the pulmonary hypertension, blood flow obstruction and right heart failure. In view of the immense clinical need, new therapies are being developed by pharmaceutical companies to treat pulmonary hypertension. This update will focus on the current development status of endotheli receptor antagonists and nitric oxide donors for the treatment of pulmonary hypertension.
AB - Pulmonary hypertension can occur idiopathically as a primary disorder of the pulmonary circulation or more commonly, it can exist as a haemodynamic manifestation of a wide variety of pulmonary and cardiovascular diseases, including acute lung injury, chronic obstructive lung disease, congenital heart disease, mitral stenosis, chronic left-sided congestive heart failure and connective tissue diseases such as scleroderma. Pulmonary hypertension is associated with changes in vascular tone as well as vascular structure, with the relative contribution of each dependent upon the aetiology of the increased pulmonary vascular resistance. Most currently available treatment utilise anticoagulants as well as vasodilator drugs that only attenuate the vasoconstrictive component of the disease. The latter category includes oral calcium channel blockers, iv. and aerosolised prostacyclin analogues and inhaled nitric oxide but all three classes of vasodilators have disadvantages and limitations. Treatment with vasodilators is often ineffective in patients with longstanding pulmonary hypertension in which structural changes contribute significantly to the pulmonary hypertension, blood flow obstruction and right heart failure. In view of the immense clinical need, new therapies are being developed by pharmaceutical companies to treat pulmonary hypertension. This update will focus on the current development status of endotheli receptor antagonists and nitric oxide donors for the treatment of pulmonary hypertension.
KW - Endothelin
KW - Endothelin receptors
KW - ET and ET antagonists
KW - Nitric oxide
KW - NO donors
KW - Pulmonary hypertension
UR - http://www.scopus.com/inward/record.url?scp=0034940315&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034940315&partnerID=8YFLogxK
U2 - 10.1517/13543784.10.7.1291
DO - 10.1517/13543784.10.7.1291
M3 - Article
VL - 10
SP - 1291
EP - 1308
JO - Expert Opinion on Investigational Drugs
JF - Expert Opinion on Investigational Drugs
SN - 1354-3784
IS - 7
ER -